Fairbanks Pharmaceuticals

Fairbanks Pharmaceuticals Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $3.02M
Latest Deal Amount
  • Investors
  • 5

Fairbanks Pharmaceuticals General Information

Description

Developer of therapies intended for treating diabetes patients. The companies therapies enhance the recently discovered transdifferentiation process in which other islet cell types are converted into beta cells, providing patients with an alternative to control their type 1 and type 2 diabetes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Therapeutic Devices
Primary Office
  • 158 Laurel Street
  • Concord, MA 01742
  • United States

Fairbanks Pharmaceuticals Timeline

2017201820192020
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Fairbanks Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 09-Oct-2018 $3.02M Completed Startup
1. Accelerator/Incubator 02-Mar-2017 Completed Startup

Fairbanks Pharmaceuticals Executive Team (2)

Name Title Board Seat Contact Info
Alan Schneyer Ph.D Co-Founder, Director, Chief Executive Officer & President
Elissa Brown Co-Founder, Chief Operating Officer, Treasurer & Secretary

Fairbanks Pharmaceuticals Investors (5)

To view Fairbanks Pharmaceuticals‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Boehringer Ingelheim Corporation 000 0000 000000 0
Boehringer Ingelheim Venture Fund Corporate Venture Capital 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
MassCONNECT Accelerator/Incubator 000 0000 000000 0

Ready to get started?

Request a free trial